High invasion and
metastasis are the major obstacles to successful breast cancertherapy.
Indocyanine green (ICG), a
photosensitizer for
photothermal therapy (PTT), shows potent anticancer efficacy when combined with the chemotherapeutic drug
doxorubicin (DOX).
Human serum albumin (HSA), a biocompatible carrier material, has been successfully used for the delivery of
paclitaxel (
Abraxane). In addition, there are ICG functional binding regions in HSA. Thus, a smart assembled nanoplatform (DI@HSA NPs) was constructed to achieve the synergistic effects of chemo-
photothermal therapy against
breast cancer. Compared to free ICG and free DOX, DI@HSA NPs showed satisfactory stability and exhibited an enhanced
tumor targeting capacity. The mild
hyperthermia generated by DI@HSA NPs can not only cause
tumor photothermal ablation and promote the uptake of DI@HSA NPs by 4T1 cells, but also protect the healthy tissues nearby the
tumor from overheating injury. More importantly, DI@HSA NPs greatly amplified the infiltration of CD4+ T cells and CD8+ T cells, resulting in inhibited
tumor growth and
metastasis. DI@HSA NPs, as a simple biocompatible nanoagent, showed excellent inhibition of
breast cancer growth and
metastasis by chemo-
photothermal therapy, providing a potential strategy for the future
therapy of
breast cancer.